



Friday, Dec. 8

7:45 – 8 a.m. Welcome and Introductions

Cathleen Gates

Chief Executive Officer, American College of Cardiology

B. Hadley Wilson, MD, FACC

President, American College of Cardiology

Srihari S. Naidu, MD, FACC

President, New York State Chapter of the American College of Cardiology

Cardiovascular and Coronary Artery Disease: Challenges in 2023

Session I: Evolving New Frontiers of Imaging Ready For Practice

Chair: B. Hadley Wilson, MD, FACC

8 – 8:25 a.m. Evolving High Predictability by Age 20-50 Years of Later CV Events and Dementia: The CARDIA (Risk Frs), PESA and BIOIMAGE (Femoral and Carotid VUS) Studies
Valentin Fuster, MD, PhD, MACC

8:25 – 8:50 a.m. Evolving Imaging Approaches For a Full Evaluation of Coronary Disease: CTA Anatomy, Plaque Structure and Functional Characteristics
Leslee J. Shaw, PhD, FACC

8:50 – 9:10 a.m. Evolving Tools Interpreting and Targeting Vasomotion Dependent Ischemia Epicardial, Microvasculature and Takotsubo Syndromes
Viviany R. Taqueti, MD, MPH, FACC

9:10 – 9:35 a.m. Panel Discussion
Valentin Fuster, MD, PhD, MACC; Leslee J. Shaw, PhD, FACC; and Viviany R. Taqueti, MD, MPH, FACC

9:35 – 9:50 a.m. Break
Visit the Expo

Session II: Acute Coronary Syndrome and COVID Advances

Chair: Deepak L. Bhatt, MD, MPH, FACC



- 9:50 – 10:15 a.m.** STEMI and Non-STEMI Types 1 and 2: Evolving Answers to Ten Recent Critical Questions, Five of Each
Deepak L. Bhatt, MD, MPH, FACC
- 10:15 – 10:40 a.m.** Evolving Strategies of Antithrombotic Therapy in Four Stages of CAD, ACS, Post PCI 1, 6 and 12 Months, Chronic CAD; Post MI LV Dysfunction
Dominick J. Angiolillo, MD, PhD, FACC
- 10:40 – 11 a.m.** Evolved Subacute and Chronic Impact of COVID-19 on Cardiovascular Sequelae
Autonomic Nervous System Dysfunction (ANS) as a Primary Concern
Tyler J. Gluckman, MD, FACC
- 11 – 11:30 a.m.** Panel Discussion
Deepak L. Bhatt, MD, MPH, FACC; Dominick J. Angiolillo, MD, PhD, FACC; Tyler J. Gluckman, MD, FACC
- 11:30 a.m. – 1 p.m.** Break
Lunch and Visit the Expo
- 11:45 a.m. – 1 p.m.** Sponsored Lunch Symposium

Session III: Chronic Coronary Disease, Stroke and Pulmonary Embolism

- 1 – 1:25 p.m.** Evolution in the Management of Stable Coronary MVD, CABG, PCI, CABG vs PCI, OMT vs CABG/PCI
Valentin Fuster, MD, PhD, MACC
- 1:25 – 1:50 p.m.** Evolving Strategies For The Management of Cerebrovascular Disease, Carotid Disease, Ischemic Stroke and Hemorrhagic Stroke
Elisabeth B. Marsh, MD
- 1:50 – 2:15 p.m.** Evolving Advances in DVT and Pulmonary Emboli Evaluation, Prevention and Management
Gregory Piazza, MD, MS, FACC
- 2:15 – 2:45 p.m.** Panel Discussion
Valentin Fuster, MD, PhD, MACC; Elisabeth B. Marsh, MD; and Gregory Piazza, MD, MS, FACC
- 2:45 – 3 p.m.** Break
Visit the Expo



Session IV: Trends and Challenges of Approaching Prevention – Health Factors

Chair: Carl J. Lavie Jr., MD, FACC

- 3 – 3:20 p.m.** **Cardiorespiratory Fitness: Peak O₂ / MET's - Survival Physical Activity as the Best Investment in Preventive CV Medicine**
Carl J. Lavie Jr., MD, FACC
- 3:20 – 3:40 p.m.** **Obesity as a Huge Epidemiological Challenge From Genetics and Behavior to New Pharmacotherapy and Bariatric Surgery**
Tiffany Powell-Wiley, MD, MPH
- 3:40 – 4 p.m.** **Lipid-Modifying Agents as a Continuous Success Development From Statins to PCSK9 Inhibitors/Inclisiran and ANGPTL3 Inhibitors**
Robert S. Rosenson, MD, FACC
- 4 – 4:20 p.m.** **Diabetic-Modifying Agents in Evolution From Metformin to SGLT2 Inhibitors, GLP1 Receptor Agonists and Beyond**
David Preiss, MD, PhD
- 4:20 – 4:40 p.m.** **Hypertension as Number One Killer of CVD Seems to Be Neglected: An Obsession on BP Levels But Not in Identifying and Following the Affected**
Franz H. Messerli, MD, FACC
- 4:40 – 5 p.m.** **Panel Discussion**
Carl J. Lavie Jr., MD, FACC; Tiffany Powell-Wiley, MD, MPH; Robert S. Rosenson, MD, FACC; David Preiss, MD, PhD; and Franz H. Messerli, MD, FACC
- 5 p.m.** **Adjournment**

Saturday, Dec. 9

Cardio-Pulmonary and Electrical Failure 2023

Session V: Myocardial Disease and Heart Failure: Basis For Management

Chair: Maria R. Costanzo, MD, FACC



- 8 – 8:20 a.m.** Evolving Imaging Approaches (MRI, PET) For 7 Myocardial Diseases: Myocarditis, DCM, HCM, NCLV, Amyloid CM, Sarcoid and Takotsubo - Diagnostic and Prognostic Implications
Christopher Kramer, MD, FACC
- 8:20 – 8:40 a.m.** Evolving Clinical Genetics and Omics in Seven Myocardial Diseases: Which Subgroup or When Should Be Gene Tested
Amy Kontorovich, MD, PhD, FACC
- 8:40 – 9 a.m.** HFrEF vs HFief vs HFpEF Phenotypes: Evolving Role of Beta-blockers, ARNI, SGLT2i and MRAs in the Three Entities
Maria R. Costanzo, MD, FACC
- 9 – 9:20 a.m.** Heart Failure, Chronic Kidney Disease and Diabetes: Evolving Role of SGLT2i in the Three Entities, Independent or Combined
Biykem Bozkurt, MD, PhD, FACC
- 9:20 – 9:40 a.m.** Myocarditis, AL/TTR Amyloid and NCLV: Evolving Approaches to These Three Challenging Myocardial Diseases
Mathew S. Maurer, MD, FACC
- 9:40 – 10 a.m.** Assist Devices and/or Transplantation in Cardiac Decompensation: Evolving Use of LVADs vs Impella vs ECMO and/or Donor Developments
Sean P. Pinney, MD, FACC
- 10 – 10:30 a.m.** Panel Discussion
Christopher Kramer, MD, FACC; Amy Kontorovich, MD, PhD, FACC; Maria R. Costanzo, MD, FACC; Biykem Bozkurt, MD, PhD, FACC; Mathew S. Maurer, MD, FACC; and Sean P. Pinney, MD, FACC
- 10:30 – 10:45 a.m.** Break
Visit the Expo

Session VI: Rhythm Disorders, Contemporary and Future Topics of Focus

Chair: Francis E. Marchlinski, MD, FACC

- 10:45 – 11:05 a.m.** Atrial Fibrillation: Evolving Clinical Challenges, Quality of Life and Preventing Stroke — Last Year Developments
Valentin Fuster, MD, PhD, MACC
- 11:05 – 11:20 a.m.** Atrial Fibrillation: Evolving Ablation Tools and LAA Closure — Who, When, How and Long Term Results?

**Agenda as of Dec. 7, 2023. Subject to change.*



Vivek Y. Reddy, MD

- 11:20 – 11:35 a.m. Vasovagal Syncope and POTS: Cardioneuroablation and Evolving Therapies**
Josef Kautzner, MD, PhD
- 11:35 – 11:50 a.m. Ventricular Tachycardia: Catheter Ablation — Who, When, How and Long Term Results?**
Francis E. Marchlinski, MD, FACC
- 11:50 – 12:05 p.m. Follow Up of Three Device Therapeutic Approaches: CRTs, Subcutaneous ICDs, Leadless Pacemakers — Who, When, How and Long Term Results?**
Jeanne E. Poole, MD, FACC
- 12:05 – 12:30 p.m. Panel Discussion**
Valentin Fuster, MD, PhD, MACC; Vivek Y. Reddy, MD; Josef Kautzner, MD, PhD; Francis E. Marchlinski, MD, FACC; and Jeanne E. Poole, MD, FACC
- 12:30 – 2 p.m. Break**
Lunch and Visit the Expo
- 12:45 – 2 p.m. Sponsored Lunch Symposium**

Valvular Heart Disease and Aorta: Challenges in 2023

Session VII: Management of Aortic Valve Disease and Aorta
Chair: Robert O. Bonow, MD, MACC

- 2 – 2:20 p.m. The Ten Major Advances in Structural Heart Disease in 2022-2023**
Samin K. Sharma, MBBS, FACC
- 2:20 – 3 p.m. Aortic Valvular Disease: Nine Diagnostic and Management Challenges**

Aortic Stenosis	Asymptomatic	When to Intervene?
Aortic Stenosis	Congenital Bicuspid	TAVR vs SVAR
Aortic Stenosis	Low Surgical Risk	TAVR vs SVAR (ie Ross)
Aortic Stenosis	Significant CAD	TAVR vs SVAR
Aortic Stenosis	Associated Mitral R	TAVR vs SVAR
Aortic Stenosis	Low Flow/Low Gradient	TAVR vs SVAR
Aortic Insufficiency	Asymptomatic	When to Intervene
Aortic Insufficiency	Without Dilated Aorta	TAVR vs SVAR

**Agenda as of Dec. 7, 2023. Subject to change.*



Aortic Stenosis/ Aortic Insufficiency	Both Moderate	TAVR vs SAVR
--	----------------------	---------------------

Presenter: Martin B. Leon, MD, FACC
 Discussants: David H. Adams, MD, FACC; Robert O. Bonow, MD, MACC; Ismail El-Hamamsy, MD, PhD; Rebecca T. Hahn, MD, FACC; Samin K. Sharma, MBBS, FACC; and Gregg W. Stone, MD, FACC

3 – 3:25 p.m. **The Dilated Thoracic and Abdominal Aorta: Evolving Understanding of the Basic Biology and Management**
 Presenter: Valentin Fuster, MD, PhD, MACC
 Discussant: Ismail El-Hamamsy, MD, PhD

3:25 – 3:40 p.m. **Break**
 Visit the Expo

Session VIII: Management of Mitral Regurgitation, Tricuspid Regurgitation and Hypertrophic Cardiomyopathy
 Chair: David H. Adams, MD, FACC

3:40 – 4:15 p.m. **Mitral Regurgitation: Five Diagnostic and Management Challenges**

Primary Mitral Regurgitation	Asymptomatic	When to Intervene?
Primary Mitral Regurgitation	Significant , Age 30	EtE R vs SMVR
Primary Mitral Regurgitation	Significant , Age 60	EtE R vs TMVR vs SMVR
Secondary Mitral Regurgitation	Significant, EF/RF?	EtE R vs OMT Alone
Secondary Mitral Regurgitation	Significant, PH/TR?	EtE R vs OMT Alone

Presenter: Robert O. Bonow, MD, MACC
 Discussants: David H. Adams, MD, FACC; Ismail El-Hamamsy, MD, PhD; Rebecca T. Hahn, MD, FACC; Martin B. Leon, MD, FACC; Samin K. Sharma, MBBS, FACC; and Gregg W. Stone, MD, FACC

4:15 – 4:35 p.m. **Tricuspid Regurgitation: Four Diagnostic and Management Challenges**

Tricuspid Regurgitation	Symptomatic or Not	When Consider Intervention?
--------------------------------	---------------------------	------------------------------------

**Agenda as of Dec. 7, 2023. Subject to change.*



Tricuspid Regurgitation	Primary Without PH	TEER vs STVR
Tricuspid Regurgitation	Secondary to PH/MVD	What Type of Intervention?
Tricuspid Regurgitation	Secondary to PH without MVD	OMT vs Intervention

Presenter: Rebecca T. Hahn, MD, FACC

Discussants: David H. Adams, MD, FACC; Robert O. Bonow, MD, MACC; Ismail El-Hamamsy, MD, PhD; Martin B. Leon, MD, FACC; Samin K. Sharma, MBBS, FACC; and Gregg W. Stone, MD, FACC

4:35 – 5 p.m. **Hypertrophic Cardiomyopathy: Five Challenging Questions — Genetic/Acquired, Mavacamten, Myectomy, Apical and Sudden Death**
Steve R. Ommen, MD, FACC

5 p.m. **Adjournment**

Sunday, Dec. 10

Year in Review: Ten Highlights of Progress in 2023

Session IX: Novelties on Pharmacology, Clinical and Epidemiological CV Science

Chair: Valentin Fuster, MD, PhD, MACC

8 – 8:20 a.m. **Disrupting the Care of Cardiovascular Disease With Single-course Gene Editing Medicines**
Amit V. Khera, MD, MSc

8:20 – 8:40 a.m. **Gut Microbiome and Heart Disease: Understanding and Future Management**
W. H. Wilson Tang, MD, FACC

8:40 – 9 a.m. **Inflammasome and Atherosclerosis**
Alan Tall, MD

9 – 9:20 a.m. **Interleukin 1 Inhibitors: Idiopathic Recurrent Pericarditis**
Allan L. Klein, MD, CM, FACC

9:20 – 9:40 a.m. **Immune Checkpoint Therapies - Myocardial and Coronary Side Effects**
Bonnie Ky, MD, MSCE, FACC

**Agenda as of Dec. 7, 2023. Subject to change.*



- 9:40 – 10 a.m. **Detection and Management of Vulnerable Plaque: Intravascular Imaging**
Akiko Maehara, MD
- 10 – 10:20 a.m. **Triglycerides: What Are the Questions?**
Robert S. Rosenson, MD, FACC
- 10:20 – 10:40 a.m. **Evolving Technological Advances in Cardiovascular Imaging**
Marcelo F. Di Carli, MD
- 10:40 – 11 a.m. **Transcatheter Intervention in CHD: Septal Defects and Valve Dysfunction**
C. Huie Lin MD, PhD, FACC
- 11 – 11:20 a.m. **Early Detection of Atherothrombotic Disease and Monitoring: EDM Program**
Borja Ibanez, MD, PhD
- 11:20 – 11:50 a.m. **Global Trends in Cardiovascular Diseases and Mortality Rates**
Valentin Fuster, MD, PhD, MACC
- 11:50 a.m. **Adjourn**